Spots Global Cancer Trial Database for Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma
Official Title: A Pilot Study of Immunotherapy Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma
Study ID: NCT05488366
Conditions
Study Description
Brief Summary: This is a pilot study determining the feasibility of combination treatments, pembrolizumab and stereotactic ablative radiotherapy (SBRT) in subjects with soft-tissue sarcoma. These are subjects who have metastatic disease initially, or recurrent or progressive disease that is not eligible for curative surgery.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
Contact Details
Name: Jeremy Harris, MD, MPhil
Affiliation: University of California, Irvine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
